Innovative Steps in Respiratory Care
Synairgen plc, a pioneering player in respiratory drug development, has made headlines recently by securing £18 million aimed at funding an influential Phase 2 clinical trial. This trial, designated the INVENT trial, is focused on evaluating SNG001, a promising drug candidate designed to assist patients who are currently reliant on mechanical ventilation due to serious viral lung infections.
Funding Details and Financial Insights
The financing for this substantial funding achievement came primarily from a subscription by TFG Asset Management. While the raise included additional financial inputs from a Bookbuild and an Open Offer, these latter efforts fell short of the £2.9 million minimum needed, resulting in no shares being issued from these sources. Participants in the Open Offer will see their funds returned as a part of this decision.
CEO's Perspective on SNG001
Expressing a sense of accomplishment, Richard Marsden, the CEO, highlighted the critical nature of SNG001 and its potential to substantially lower mortality rates among critically ill patients. As preparations continue, the trial is expected to commence shortly, aligning with urgent demands for innovative therapeutic solutions in respiratory care.
Utilization of Funds for Trial Costs
The £18 million funding is allocated to cover various crucial expenses associated with the trial. This includes both external and internal costs up to the point of Interim Analysis, as well as essential drug manufacturing and stability testing. The financial strategy demonstrates a thoughtful and deliberate approach to managing resources in the face of pressing healthcare needs.
Market Adjustments and Shareholder Implications
In an important move, the company's shares are slated for removal from trading on the AIM market, but this is contingent upon receiving approval from shareholders during an upcoming General Meeting scheduled to take place on January 16, 2025. Should these resolutions receive the green light, it will pave the way for the issuance of 900 million new Ordinary Shares.
New Shares and Market Readiness
In conjunction with this financial maneuver, the London Stock Exchange has processed an application for the listing of the new shares on AIM, with an anticipated admission date set for January 17, 2025. Once approved, these shares will enjoy equal access to dividends and distributions as their existing counterparts.
Chairman's Commitment to Patients
Mark Parry-Billings, the Chairman, emphasized the tremendous potential of SNG001 and reinforced the significance of the INVENT trial, particularly for patients in intensive care units. Closing with appreciation, he thanked shareholders for their unwavering support and expressed eagerness in providing continued updates on the trial's progress.
Frequently Asked Questions
What is the purpose of the INVENT trial?
The INVENT trial aims to assess the efficacy of the drug candidate SNG001 in ventilated patients suffering from severe viral lung infections.
How much funding has Synairgen secured?
Synairgen has successfully raised £18 million to support the trial.
Who provided the funding for the trial?
The funding was primarily secured through TFG Asset Management, along with additional commitments from a Bookbuild.
When will the trial begin?
The trial is expected to commence in the upcoming months, addressing urgent treatment needs for critically ill patients.
What will happen to Synairgen's shares?
Synairgen's shares are set to be removed from trading on the AIM market, pending shareholder approval, with plans for new Ordinary Shares to be issued if approved.
